ScholarIQanswers from OpenAlex & ORCID
Hugh J. McMillan
ResearcherPublications, citations & collaboration network
Hugh J. McMillan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hugh J. McMillan have?
ScholarIQindexed works
Hugh J. McMillan has 256 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hugh J. McMillan have?
ScholarIQcitation count
Hugh J. McMillan has 6,060 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hugh J. McMillan?
ScholarIQh-index
Hugh J. McMillan has an h-index of 40 in OpenAlex.
What is the i10-index of Hugh J. McMillan?
ScholarIQi10-index
Hugh J. McMillan has an i10-index of 105 in OpenAlex.
What is the ORCID of Hugh J. McMillan?
ScholarIQorcid
The ORCID for Hugh J. McMillan is on the source record.
What is the OpenAlex record for Hugh J. McMillan?
ScholarIQopenalex
The OpenAlex for Hugh J. McMillan is on the source record.
What are the most-cited papers on Hugh J. McMillan?
ScholarIQmost cited works
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Parsons, Perry B. Shieh, Sarah Kavanagh, Sitra Tauscher‐Wisniewski, Bryan E. McGill, Thomas A. Macek
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa H. Chand, F. Mohr, Hugh J. McMillan, F Tukov, Kyle H. Montgomery, A. de Kleyn, Rui Sun, Sitra Tauscher‐Wisniewski, Petra Kaufmann, Gerd A. Kullak‐Ublick
Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
Erik Landfeldt, Rachel Thompson, Thomas Sejersen, Hugh J. McMillan, Janbernd Kirschner, Hanns Lochmüller
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Parsons, Perry B. Shieh, Sarah Kavanagh, Melissa Wigderson, Sitra Tauscher‐Wisniewski, Bryan E. McGill, Thomas A. Macek
Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
Craig Campbell, Hugh J. McMillan, Jean K. Mah, Mark A. Tarnopolsky, Kathryn Selby, Ty McClure, Dawn Wilson, Matthew L. Sherman, Diana M. Escolar, Kenneth M. Attie